Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Myelin-specific Th17 cells induce severe relapsing optic neuritis with irreversible loss of retinal ganglion cells in C57BL/6 mice.
Epigenetic Modulation of Human Induced Pluripotent Stem Cell Differentiation to Oligodendrocytes.
Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience.
Multiple sclerosis: A lifestyle disease?
Getting a Handle on Lymphopenia With Tecfidera
A Unified Frequency Domain Model to Study the Effect of Demyelination on Axonal Conduction.
Multiple sclerosis and risk of young-adult-onset Hodgkin lymphoma.
24th Biennial Meeting ISN/ASN 2013
Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study.
195 How Well Do Neuroradiologists Predict the Side of Trigeminal Neuralgia?
Emerging oral agents for multiple sclerosis.
Multifocal Tumefactive Demyelination Mimicking Intracranial Neoplasm.
Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety.
Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone.
Optic neuritis: a 5-year follow-up study of Chinese patients based on aquaporin-4 antibody status and ages.
Sex differences in comorbidity at diagnosis of multiple sclerosis: A population-based study.
Masitinib in Patients with Progressive or Relapse-Free Secondary Multiple Sclerosis
Glatiramer acetate inhibits degradation of collagen II by suppressing the activity of interferon regulatory factor-1.
Current and future immunotherapy targets in autoimmune neurology.
DNA strand breakage by peroxidase-activated mitoxantrone.
Interferon beta-1b therapy in chronic viral dilated cardiomyopathy--is there a role for specific therapy?
Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide.
Cannabinoids for Medical Use: A Systematic Review and Meta-analysis.
Dimethyl fumarate (BG-12, Tecfidera) - NICE says yes in draft final guidance
The cytoskeleton as a novel therapeutic target for old neurodegenerative disorders.

Pages